Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 42, 2005, Pages 6607-6612

  Gad, Amal ^a,b   Tanaka, Eiji ^a   Matsumoto, Akihiro ^a   Wahab, Matsumoto Abd El ^a   Serwah, Abd El Hamid ^b   Attia, Fawzy ^b   Ali, Khalil ^b   Hassouba, Howayda ^b   El Deeb, Abd El Raoof ^b   Ichijyo, Tetsuya ^a   Umemura, Takeji ^a   Muto, Hidetomo ^a   Yoshizawa, Kaname ^a   Kiyosawa, Kendo ^a,c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Liver disease; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CARBOHYDRATE ANTIGEN; KL 6 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER INVASION; CHOLESTASIS; CHRONIC LIVER DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; ETHNIC GROUP; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREDICTION; PROTEIN BLOOD LEVEL; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; VITAMIN K DEFICIENCY;

EID: 30444433822     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i42.6607     Document Type: Article

References (23)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154
2. Szilagyi A, Alpert L. Clinical and histopathological variation in hepatocellular carcinoma. Am J Gastroenterol 1995; 90: 15-23
3. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335
4. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6: 320-325
5. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159
6. Iwai M, Kashiwadani M, Takino T, Ibata Y. Demonstration by light and ultrastructural immunoperoxidase study of alpha-fetoprotein-positive non-hepatoma cells and hepatoma cells during 3′-methyl-4-dimethylaminoazobenzene hepatocarcinogenesis. Virchows Arch B Cell Pathol Incl Mol Pathol 1988; 55: 117-123
7. McIntire KR, Waldmann TA, Moertel CG, Go VL, Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res 1975; 35: 991-996
8. Gallo V, Cerutti E, Riberi A, Re M, Petrino R, Pecchio F. Alpha-fetoprotein and tissue polypeptide antigen in non neoplastic hepatic disorders. J Nucl Med Allied Sci 1989; 33: 89-93
9. Alpert E, Feller ER. Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 1978; 74: 856-858
10. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417
11. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73
12. Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl 1994; 8: 6-26
13. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129: 255-265
14. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999; 46: 151-158
15. Sagara M, Yonezawa S, Nagata K, Tezuka Y, Natsugoe S, Xing PX, McKenzie IF, Aikou T, Sato E. Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis. Int J Cancer 1999; 84: 251-257
16. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998; 4: 2605-2614
17. Tanimoto T, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. MUC1 expression in intramucosal colorectal neoplasms. Possible involvement in histogenesis and progression. Oncology 1999; 56: 223-231
18. Suzuki K, Takada H, Oka S, Kanouzawa S, Iimuro M, Kitazumi Y, Arima T, Ohyama R, Kuwayama H. Clinical significance of KL-6, a marker of interstitial pneumonia, in cases of HCV-associated chronic liver disease. Intern Med 2003; 42: 650-654
19. Moriyama M, Matsumura H, Mikuni M, Arkawa Y, Ohshiro S, Aoki H, Yamagami H, Kaneko M, Shioda A, Saito H, Tanaka N, Arakawa Y. The clinical significance of serum KL-6 levels in patients with type C liver diseases. Hepatol Res 2003; 25: 385-395
20. Moriyama M, Matsumura H, Watanabe A, Nakamura H, Arakawa Y, Oshiro S, Aoki H, Shimizu T, Yamagami H, Kaneko M, Shioda A, Tanaka N, Arakawa Y. Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma. Hepatol Res 2004; 30: 24-33
21. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997; 17: 501-507
22. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33: 123-126
23. Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998; 89: 1241-1250